miRNA expression profiling of inflammatory breast cancer identifies a 5‐miRNA signature predictive of breast tumor aggressiveness

IBC (inflammatory breast cancer) is a rare but very aggressive form of breast cancer with a particular phenotype. The molecular mechanisms responsible for IBC remain largely unknown. In particular, genetic and epigenetic alterations specific to IBC remain to be identified. MicroRNAs, a class of small noncoding RNAs able to regulate gene expression, are deregulated in breast cancer and may therefore serve as tools for diagnosis and prediction. This study was designed to determine miRNA expression profiling (microRNAome) in IBC. Quantitative RT‐PCR was used to determine expression levels of 804 miRNAs in a screening series of 12 IBC compared to 31 non‐stage‐matched non‐IBC and 8 normal breast samples. The differentially expressed miRNAs were then validated in a series of 65 IBC and 95 non‐IBC. From a set of 18 miRNAs of interest selected from the screening series, 13 were differentially expressed with statistical significance in the validation series of IBC compared to non‐IBC. Among these, a 5‐miRNA signature comprising miR‐421, miR‐486, miR‐503, miR‐720 and miR‐1303 was shown to be predictive for IBC phenotype with an overall accuracy of 89%. Moreover, multivariate analysis showed that this signature was an independent predictor of poor Metastasis‐Free Survival in non‐IBC patients.

[1]  R. Gatti,et al.  ATM is down-regulated by N-Myc–regulated microRNA-421 , 2010, Proceedings of the National Academy of Sciences.

[2]  S. Fuqua,et al.  Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expression , 2011, Oncogene.

[3]  I. Van der Auwera,et al.  Integrated miRNA and mRNA expression profiling of the inflammatory breast cancer subtype , 2010, British Journal of Cancer.

[4]  G. Hortobagyi,et al.  Trends for inflammatory breast cancer: is survival improving? , 2007, The oncologist.

[5]  W. Woodward,et al.  Identifying factors that impact survival among women with inflammatory breast cancer. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  F. Bertucci,et al.  Gene Expression Profiling for Molecular Characterization of Inflammatory Breast Cancer and Prediction of Response to Chemotherapy , 2004, Cancer Research.

[7]  F. Basile,et al.  Specific Alterations of MicroRNA Transcriptome and Global Network Structure in Colorectal Carcinoma after Cetuximab Treatment , 2010, Molecular Cancer Therapeutics.

[8]  N. Palanisamy,et al.  Genomic Loss of miR-486 Regulates Tumor Progression and the OLFM4 Antiapoptotic Factor in Gastric Cancer , 2011, Clinical Cancer Research.

[9]  Rosette Lidereau,et al.  Molecular Profiling of Inflammatory Breast Cancer , 2004, Clinical Cancer Research.

[10]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.

[11]  Daniel Birnbaum,et al.  Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. , 2005, Cancer research.

[12]  S. Devesa,et al.  Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. , 2005, Journal of the National Cancer Institute.

[13]  G. Hortobagyi,et al.  Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  F. Bertucci,et al.  Immunophenotypic analysis of inflammatory breast cancers: identification of an ‘inflammatory signature’ , 2004, The Journal of pathology.

[15]  Sofia D. Merajver,et al.  RhoC-GTPase is a Novel Tissue Biomarker Associated with Biologically Aggressive Carcinomas of the Breast , 2005, Breast Cancer Research and Treatment.

[16]  S. Vacher,et al.  Quantification of PKC family genes in sporadic breast cancer by qRT‐PCR: Evidence that PKCι/λ overexpression is an independent prognostic factor , 2012, International journal of cancer.

[17]  B. Qian,et al.  High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-β1 , 2009, Breast Cancer Research and Treatment.

[18]  Luc Y. Dirix,et al.  Distinct Molecular Signature of Inflammatory Breast Cancer by cDNA Microarray Analysis , 2005, Breast Cancer Research and Treatment.

[19]  E. van Marck,et al.  Distinct molecular phenotype of inflammatory breast cancer compared to non-inflammatory breast cancer using Affymetrix-based genome-wide gene-expression analysis , 2007, British Journal of Cancer.

[20]  C. Balch,et al.  AJCC Cancer Staging Manual. 6th ed , 2002 .

[21]  S. Merajver,et al.  International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  J. Steitz,et al.  Switching from Repression to Activation: MicroRNAs Can Up-Regulate Translation , 2007, Science.

[23]  I. Bozzoni,et al.  Concerted microRNA control of Hedgehog signalling in cerebellar neuronal progenitor and tumour cells , 2008, The EMBO journal.

[24]  Y. Mo,et al.  Systematic validation of predicted microRNAs for cyclin D1 , 2009, BMC Cancer.

[25]  S. Hilsenbeck,et al.  Molecular Heterogeneity of Inflammatory Breast Cancer: A Hyperproliferative Phenotype , 2006, Clinical Cancer Research.

[26]  John W M Martens,et al.  Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer , 2008, Proceedings of the National Academy of Sciences.

[27]  Edith A Perez,et al.  MicroRNA signatures: clinical biomarkers for the diagnosis and treatment of breast cancer. , 2011, Trends in molecular medicine.

[28]  E. van Marck,et al.  Relapse-Free Survival in Breast Cancer Patients Is Associated with a Gene Expression Signature Characteristic for Inflammatory Breast Cancer , 2008, Clinical Cancer Research.

[29]  W. Gong,et al.  Downregulation of Human Farnesoid X Receptor by miR-421 Promotes Proliferation and Migration of Hepatocellular Carcinoma Cells , 2012, Molecular Cancer Research.

[30]  Fang Zhou,et al.  A 5-MicroRNA Signature for Lung Squamous Cell Carcinoma Diagnosis and hsa-miR-31 for Prognosis , 2011, Clinical Cancer Research.

[31]  Anthony Fyles,et al.  MicroRNA-301 mediates proliferation and invasion in human breast cancer. , 2011, Cancer research.

[32]  C. Croce,et al.  Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[33]  Daniel Birnbaum,et al.  High-Resolution Comparative Genomic Hybridization of Inflammatory Breast Cancer and Identification of Candidate Genes , 2011, PloS one.

[34]  Christophe Lemetre,et al.  MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer , 2009, Breast Cancer Research.

[35]  Ken Saito,et al.  Vasculogenic mimicry and pseudo‐comedo formation in breast cancer , 2002, International journal of cancer.

[36]  Sakari Knuutila,et al.  MicroRNA profiling differentiates colorectal cancer according to KRAS status , 2012, Genes, chromosomes & cancer.

[37]  Xian-gui Hu,et al.  MicroRNA 421 suppresses DPC4/Smad4 in pancreatic cancer. , 2011, Biochemical and biophysical research communications.

[38]  Andrea Bild,et al.  Gene Expression Profiles of Multiple Breast Cancer Phenotypes and Response to Neoadjuvant Chemotherapy , 2006, Clinical Cancer Research.

[39]  Israel Steinfeld,et al.  Novel Rank-Based Statistical Methods Reveal MicroRNAs with Differential Expression in Multiple Cancer Types , 2009, PloS one.

[40]  C. Croce,et al.  MicroRNA gene expression deregulation in human breast cancer. , 2005, Cancer research.

[41]  Hui Li,et al.  MicroRNA-421 functions as an oncogenic miRNA in biliary tract cancer through down-regulating farnesoid X receptor expression. , 2012, Gene.

[42]  Rosette Lidereau,et al.  BMC Cancer BioMed Central Research article NF-kappa B genes have a major role in Inflammatory Breast Cancer , 2008 .

[43]  Leonard D. Goldstein,et al.  MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype , 2007, Genome Biology.

[44]  D. Greco,et al.  Human Papillomavirus 16 E5 Modulates the Expression of Host MicroRNAs , 2011, PloS one.

[45]  G. Russo,et al.  MicroRNA profiling reveals that miR-21, miR486 and miR-214 are upregulated and involved in cell survival in Sézary syndrome , 2011, Cell Death and Disease.

[46]  Luc Y Dirix,et al.  Increased Angiogenesis and Lymphangiogenesis in Inflammatory versus Noninflammatory Breast Cancer by Real-Time Reverse Transcriptase-PCR Gene Expression Quantification , 2004, Clinical Cancer Research.

[47]  C. Croce,et al.  Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA , 2012, Proceedings of the National Academy of Sciences.

[48]  John S Mattick,et al.  Regulation of Epidermal Growth Factor Receptor Signaling in Human Cancer Cells by MicroRNA-7* , 2009, Journal of Biological Chemistry.

[49]  Luigi Naldini,et al.  Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications , 2009, Nature Reviews Genetics.

[50]  Y. Qi,et al.  Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer , 2011, Breast Cancer Research and Treatment.

[51]  Seigo Nakamura,et al.  Molecular targets for treatment of inflammatory breast cancer , 2009, Nature Reviews Clinical Oncology.